Navin Fluorine International Limited — PPTs, 09-05-2025: Investor Presentation

1. Financial Highlights:

Navin Fluorine reported consolidated sales of Rs. 2,349.4 Cr, up 14% YoY. Operating EBITDA rose 34% to Rs. 533.7 Cr with a 343 bps margin expansion to 22.7%. Operating profit before tax surged 48% to Rs. 336.4 Cr. Q4 sales grew 16% to Rs. 700.9 Cr, with a strong 62% jump in operating EBITDA to Rs. 178.7 Cr and margin improvement of 721 bps to 25.5%. Net debt-to-equity was a comfortable 0.37x. Operating cash flow stood at Rs. 571 Cr. Significant capex included Rs. 450 Cr on anhydrous hydrofluoric acid (AHF) capacity and Rs. 288 Cr on cGMP-compliant CDMO facilities.

2. Strategic Initiatives & Growth Drivers:

The Rs. 450 Cr AHF plant is slated for mid-FY26 commissioning to boost upstream integration. Dewas’ cGMP4 facility expansion (Rs. 288 Cr) targeting pharmaceutical fluorination is on schedule for Q3 FY26. The Dahej facility began commercial production of new specialty fluorochemicals, with two more molecules expected in Q1 FY26. Surat plant is enhancing capabilities with a Rs. 30 Cr investment. A strategic partnership with Chemours focuses on advanced materials like Opteon immersion cooling fluids, backed by a $14 million capex project underway in Surat.

3. Business Developments:

Multi-year contracts underpin a healthy order book in specialty chemicals and CDMO segments. CDMO revenues jumped 141% YoY in Q4, driven by supply agreements with major US and European pharma firms. New molecule development and scale-ups are progressing well. Commercial dispatches of higher-margin fluorospecialty chemicals have started, supported by technology partnerships such as with Buss ChemTech AG for solar- and electronic-grade hydrofluoric acid.

4. Market Position & Competitive Advantage:

Navin Fluorine is a global leader in specialty fluorochemicals with over 50 years of experience and one of India’s largest fluorination capacities. Strong backward integration lowers dependence on China. Its unique cGMP-compliant CDMO capabilities and alliances with global innovators provide technological and scale advantages. Robust R&D and diversified revenues from domestic and international markets reinforce its competitive moat.

5. Investor Implications:

Healthy margin expansion, revenue growth, and cash flows point to positive growth potential. Strategic capex and global collaborations could boost future profitability. Investors should monitor execution risks associated with multiple large projects and global market dynamics. Overall, Navin Fluorine’s innovation focus and capacity ramp-up align well with growing fluorochemical demand, supporting a resilient growth outlook.